BioCentury
ARTICLE | Finance

Pedaling to the clinic

How Bicycle plans to spend its £40 million series B round

June 9, 2017 5:07 PM UTC

With lead candidate BT-1718 expected to enter the clinic this year, Bicycle Therapeutics Ltd. has padded its coffers with a £40 million ($51.3 million) series B to expand its pipeline of bicyclic peptides for cancer.

Vertex Ventures HC, led the round, which closed on June 1. Fellow new investors Cambridge Innovation Capital and Longwood Fund also participated, along with existing investors Novartis Venture Fund, SR One, SV Life Sciences and Atlas Venture. ...

BCIQ Company Profiles

Bicycle Therapeutics plc